Option Care Health to acquire Amedisys in all-stock deal valued at ~$3.6B

Option Care Health, Inc.

Amedisys stockholders receive 3.0213 OPCH shares per AMED share, ~$97.38/AMED based on May 2 close, a 26% premium.
Combined 2022 revenue ~$6.2B, adjusted EBITDA ~$622M; OPCH holders own ~64.5%, AMED holders ~35.5%.
Expected annual run-rate synergies of ~$75M by year three (~$50M cost, ~$25M revenue).
Board to expand to 10 directors; three Amedisys directors appointed post-close.
Goldman Sachs committed $450M bridge loan facility for Amedisys debt refinancing and transaction costs.

item 1.01 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Option Care Health, Inc. entered into Agreement and Plan of Merger with Amedisys, Inc. (effective 2023-05-03).

Action: entry
Agreement: merger
Counterparty: Amedisys, Inc.
Effective: 2023-05-03

Exact text from the filing

On May 3, 2023, Option Care Health, Inc., a Delaware corporation (the " Company "), Uintah Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (" Merger Sub "), and Amedisys, Inc., a Delaware corporation (" Amedisys "), entered into an Agreement and Plan of Merger (the " Merger Agreement ").

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

Option Care Health, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-055567

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.